CORDIS
EU research results

CORDIS

English EN
European Nanomedicine Characterization Laboratory

European Nanomedicine Characterization Laboratory

Objective

In order to accelerate the development of the nanomedicine business in Europe, EU-NCL interconnects 8 European and 1 American key reference facilities with a proven expertise in physical, chemical, in vitro and in vivo biological characterisation of nanoparticles for medical applications. The objective is to reach a level of international excellence in nanomedicine characterization for all medical indication, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to the regulatory agencies in order to get the approval for clinical trials and later the marketing authorization. EU-NCL is partnered with the sole international reference facility namely the Nanotechnology Characterisation Lab of the USA to get a faster international harmonization of analytical protocols. EU-NCL is closely connected to national medicine agencies and to the European Medicine Agency in order to permanently adapt its analytical services to the need and requests of the regulators. EU-NCL is designed, organized and operated according to the highest EU regulatory and quality standards in order to provide a full analytical cascade of 42 assays. Within EU-NCL, 6 analytical facilities will offer a Trans National Access to their existing analytical services but they will also develop new or improved analytical assays under the Joint Research Activities in order to keep EU-NCL at the cutting edge of the nanomedicine characterisation. A complementary set of networking activities will make EU-NCL able to deliver to the European academic or industrial scientists the best analytical services they dramatically require for accelerating the industrial development of their candidate nanomedicines. An exploitation and business plan will be proposed at the end of the project in order to submit a sustainable development plan beyond the initial period of 4 years.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

Address

Rue Leblanc 25
75015 Paris 15

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 944 426,25

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

Belgium

EU Contribution

€ 827 472,50

EUROPEAN RESEARCH SERVICES GMBH

Germany

EU Contribution

€ 102 880

LEIDOS BIOMEDICAL RESEARCH INC

United States

EU Contribution

€ 273 700

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 442 433,75

STIFTELSEN SINTEF

Norway

EU Contribution

€ 613 910

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 650 716,25

EIDGENOSSISCHE MATERIALPRUFUNGS- UND FORSCHUNGSANSTALT

Switzerland

GESELLSCHAFT FUR BIOANALYTIK MUNSTER EV

Germany

EU Contribution

€ 866 206

SINTEF AS

Norway

EU Contribution

€ 273 436,25

Project information

Grant agreement ID: 654190

Status

Ongoing project

  • Start date

    1 May 2015

  • End date

    31 December 2019

Funded under:

H2020-EU.1.4.1.2.

  • Overall budget:

    € 5 627 303,50

  • EU contribution

    € 4 995 181

Coordinated by:

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France